CKD Bio Corp. (KRX:063160)
20,900
0.00 (0.00%)
Feb 13, 2025, 9:00 AM KST
CKD Bio Revenue
CKD Bio had revenue of 42.34B KRW in the quarter ending September 30, 2023, with 12.64% growth. This brings the company's revenue in the last twelve months to 159.93B, up 3.59% year-over-year. In the year 2022, CKD Bio had annual revenue of 156.04B with 9.70% growth.
Revenue (ttm)
159.93B
Revenue Growth
+3.59%
P/S Ratio
0.71
Revenue / Employee
308.16M
Employees
519
Market Cap
114.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 156.04B | 13.80B | 9.70% |
Dec 31, 2021 | 142.24B | 17.64B | 14.16% |
Dec 31, 2020 | 124.60B | -12.58B | -9.17% |
Dec 31, 2019 | 137.18B | 12.67B | 10.18% |
Dec 31, 2018 | 124.51B | 10.75B | 9.45% |
Dec 31, 2012 | Pro | Pro | Pro |
Dec 31, 2011 | Pro | Pro | Pro |
Dec 31, 2010 | Pro | Pro | Pro |
Dec 31, 2009 | Pro | Pro | Pro |
Dec 31, 2008 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,495.50B |
Peptron | 2.41B |
Hanall Biopharma | 134.24B |